Sep 22, 2026 · 5 min
Obesity-drug data lifts Viking as Medicare cuts hit labs
Viking Soars; On Holding Climbs; Quest Diagnostics Drops
The episode shows how clinical evidence, corporate capital returns and reimbursement policy can send sharply different signals through healthcare and consumer stocks.
- 1Viking’s obesity-drug study found patients retained much of their weight loss with less frequent dosing.
- 2On Holding rallied after authorizing a $1 billion buyback and forecasting strong third-quarter sales growth.
- 3Quest Diagnostics and Labcorp fell as preliminary Medicare rates signaled steeper laboratory-service payment cuts.
Don't miss
Viking Therapeutics surges after data suggest patients can retain most of their weight loss with less frequent dosing.
The brief
Viking Therapeutics led the action after encouraging maintenance-study data showed its injected obesity drug preserved much of patients’ weight loss with less frequent dosing.
Judy LaGrouille helps frame why the Viking data mattered: dosing frequency can shape the practical appeal of an obesity treatment, not just its headline efficacy.
On Holding rallied after authorizing up to $1 billion in share buybacks through 2029 and projecting strong third-quarter sales growth, with Kylian Mbappé adding visibility.
Quest Diagnostics and Labcorp moved lower when preliminary Medicare laboratory-service rates pointed to larger-than-expected cuts, with reductions potentially continuing into 2028 and 2029.
Taken together, the movers show how biotech data, capital allocation and reimbursement decisions can quickly reshape expectations across very different businesses.
What was said on this episode
1 statement · 1 positive
Viking’s results are an optimistic sign for GLP-1 weight-loss maintenance.
“Viking Therapeutics results are really an optimistic sign for that. particular process.”
Listen at 1:26
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Viking Therapeutics
Kylian Mbappé
Bloomberg: Business News DailyBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.